Prelude Capital Management’s ImmuCell ICCC Stock Holding History

Prelude Capital Management’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-700	Closed	-$4K	–	1554
2015 Q3	$4K	Buy	+700	New	+$5.71K	﹤0.01%	1406

Other funds holding ICCC

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

EFS

Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SKK

Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's ICCC Position: Q4 2015 in Review

Prelude Capital Management sold out of ImmuCell (ICCC) in Q4 2015, closing a stake of 700 shares — an estimated $4K sold.

Prelude Capital Management first reported a position in ICCC in Q3 2015 and held it in 1 quarter. The position peaked at $4K in Q3 2015. 15 funds tracked by Wall St. Rank hold ICCC as of Q4 2015.

Prelude Capital Management reported no remaining ImmuCell position as of Q4 2015 after selling out during the quarter.
Prelude Capital Management sold 700 ImmuCell shares in Q4 2015, an estimated $4K.
Prelude Capital Management first reported a position in ImmuCell in Q3 2015 and held it in 1 quarter.
Prelude Capital Management's ImmuCell position peaked at $4K in Q3 2015.
15 funds tracked by Wall St. Rank held ImmuCell as of Q4 2015.

Based on Prelude Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.